GSK plc
(NYSE: GSK)
Balfour Capital Group has issued a buy recommendation
for GSK plc (GSK) on September 24th, 2025
GSK plc (formerly GlaxoSmithKline) is a British multinational pharmaceutical and biotechnology company.
Its operations are primarily focused on specialty medicines, vaccines, and general medicines.
In 2022, GSK spun off its consumer health / over-the-counter business into a separate company, Haleon plc, allowing GSK to focus more on R&D, pharmaceuticals, and vaccines.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $40.52 on September 24th, 2025.
- Our designated price target stands at $65.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
2025 Q2 EARNING REPORT
A Q2 report evaluates company financials for investors.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
Balfour Capital Group wants to clarify that our recommendation to Buy GSK PLC (NYSE: GSK) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
